How would you approach adjuvant therapy for a young post-menopausal woman with a grade 3 pT1a (5mm) node negative ER+/HER2- invasive ductal carcinoma?

Would you consider gene profiling to determine need for chemotherapy?

Answer from: Medical Oncologist at Academic Institution

There is no data from the prospective trials to support genomic testing in T1a tumors. TAILORx did not enroll T1a tumors. A G3 tumor under 1cm is clinically low risk so Mammaprint would not have clinical utility either. Since NCCN doesn't recommend chemotherapy in this scenario, I would not test.

Comments

Medical Oncologist at Texas Oncology
What about ovarian suppression? I would say no.

Medical Oncologist at University of Wisconsin School of Medicine and Public Health
I agree and would not recommend genomic testing an...

Answer from: Medical Oncologist at Community Practice

I will recommend adjuvant Hormone Therapy.

Comments

Medical Oncologist at Premier Physicians network
What if this patient was premenopausal? Would you...

Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
The data in lower risk women not treated with chem...

Please select the option that best describes you:

How would you approach adjuvant therapy for a young post-menopausal woman with a grade 3 pT1a (5mm) node negative ER+/HER2- invasive ductal carcinoma?

Related Questions